Home Ingredients EpiCor® (Postbiotic Yeast Fermentate — Cargill)
Immune SupportGut Health

EpiCor® (Postbiotic Yeast Fermentate — Cargill)

Saccharomyces cerevisiae
Evidence Level
Limited
2 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

EpiCor is a postbiotic ingredient from Cargill, derived from the fermentation of Saccharomyces cerevisiae (baker's yeast) and a widely used commercial postbiotic ingredient. Originally developed and studied for immune support, with a small number of manufacturer-affiliated trials reporting reduced cold/flu-like symptoms; more recent research has examined gut health applications. A randomized double-blind placebo-controlled trial showed 500 mg/day EpiCor reduced GI discomfort and constipation symptoms in adults with mild GI dysfunction. In vitro SHIME gut model studies show EpiCor increases butyrate production, Bifidobacterium abundance, and Lactobacillus colonization, supporting prebiotic-like mechanisms. Most of the clinical evidence base is on immune outcomes, but gut-specific evidence exists at the standard 500 mg dose. Useful for both immune support and as a postbiotic for mild GI discomfort/irregularity.

Studied Dose 500 mg/day.
Active Compound Yeast fermentate from Saccharomyces cerevisiae (mix of metabolites and bioactive compounds).

Benefits

Digestive comfort and bowel regularity

A small randomized double-blind placebo-controlled pilot trial in 80 adults with gastrointestinal discomfort and constipation found that 500 mg a day improved stool consistency for the whole group and eased bloating and feeling of fullness in the moderate-symptom subgroup, versus placebo. This is the main direct gut evidence, and the trial was manufacturer linked.

Supported by Trial 1, Trial 2

Immune support in cold and flu season

Two small, single-site, manufacturer-affiliated trials of 500 mg a day, each in about 116 adults during cold and flu season, reported fewer cold and flu-like symptoms than placebo. In the trial of non-vaccinated adults the incidence fell but symptom severity did not change. The immune evidence base is larger than the gut evidence but remains limited and from a single team.

Supported by Trial 1

Postbiotic mechanism, gut microbiome modulation

In vitro SHIME® gut model studies show EpiCor increases butyrate production (the short-chain fatty acid that fuels colon cells), promotes Bifidobacterium and Lactobacilli growth, and shifts gut microbiome composition. Mechanism foundation for prebiotic-like effects without containing live bacteria.

Supported by Trial 1

Gut-immune axis support

Fermentation of this yeast postbiotic in the colon produces metabolites that may connect its gut effects to its immune effects, so it is studied across both gut and immune endpoints rather than one alone. This gut to immune link is a proposed mechanism rather than a proven clinical outcome.

Year-round daily use postbiotic

Made for ongoing daily use rather than acute illness. Because it is a postbiotic with no live bacteria, it is heat-stable and shelf-stable and needs no refrigeration, which are practical advantages over traditional live probiotics.

Pediatric immune research

One manufacturer-funded trial in 256 children aged 4 to 12 reported good tolerability and significantly lower overall cold and flu symptom severity with 500 mg a day over 84 days, along with less use of cold and flu medication, but no significant reduction in how often symptoms occurred. Pediatric evidence is limited to this single sponsored trial.

Supported by Trial 2

Mechanism of action

1

Postbiotic Bioactive Compounds

EpiCor contains beneficial mix of metabolites, β-glucans, mannans, polyphenols, peptides, and other bioactive compounds produced during yeast fermentation.

2

Innate Immune Activation

Activates innate immune cells including NK cells, macrophages, and neutrophils, the first-line immune defense.

3

sIgA Modulation

Increases secretory IgA in mucosal surfaces, the primary antibody at respiratory and GI mucosal barriers.

4

Antioxidant and Anti-Inflammatory Activity

Yeast metabolites provide antioxidant and modest anti-inflammatory effects.

5

Gut Microbiome Modulation

Modulates gut microbiome composition and supports gut-immune communication.

Clinical trials

1
EpiCor in adults during cold and flu season
PubMed

Two small, single-site, manufacturer-affiliated EpiCor 500 mg a day RCTs in adults during cold and flu season (Moyad et al. 2008 and 2010, Urol Nurs and J Altern Complement Med).

Healthy adults across studies.

Reduced incidence of cold/flu-like symptoms vs placebo; the 2010 companion trial found no significant effect on symptom severity. Trials were small, single-site, and manufacturer-affiliated.

2
EpiCor in children: a randomized controlled trial
PubMed

A manufacturer-funded trial of 500 mg a day for 84 days in children aged 4 to 12 (Singh et al. 2024, Pediatr Res).

256 children aged 4 to 12 years.

The children had good tolerability and significantly lower overall cold and flu symptom severity than placebo, with less use of cold and flu medication, but no significant reduction in how often symptoms occurred.

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated.
Mild GI distress (rare).
Allergic reactions to yeast possible; relevant for those with yeast or mold allergies.
Postbiotic (contains no live bacteria), unlike traditional probiotics.

Important Drug interactions

Generally minimal drug interactions.
Yeast allergy: verify if allergic to baker's or brewer's yeast.
Pregnancy: limited specific safety data; generally considered safe at moderate doses; consult a clinician.
Lactation: generally considered safe.
Children: limited data; one manufacturer-funded trial reported good tolerability at age-adjusted doses.

Featured in these supplement guides

Immune Support→

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble vitamin that humans cannot make, so it must…
Immune Support
Wellmune (Yeast Beta-Glucan)
Wellmune is a baker's yeast beta-1,3/1,6-D-glucan derived from a proprietary strain of Sac…
Immune Support
Zinc
Zinc is an essential trace mineral that hundreds of enzymes need, and it plays a role in i…
Immune Support
Quercetin
Quercetin is a flavonoid found in apples, berries and onions, and it is sold as a dietary…

Explore Other Ingredients

Immune Support
Probiotics (Multi-strain Blends)
Multi-strain probiotic blends combine live microbes, usually from Lactobacillus and Bifido…
Gut Health
Inulin
Inulin is a soluble fiber made of chains of fructose, extracted mainly from chicory root a…
Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body, and cells of the intestinal linin…

Frequently asked questions about EpiCor® (Postbiotic Yeast Fermentate — Cargill)

What is EpiCor?

EpiCor is a postbiotic ingredient from Cargill, derived from the fermentation of Saccharomyces cerevisiae (baker's yeast) and a widely used commercial postbiotic ingredient.

What is EpiCor used for?

EpiCor is researched primarily for Immune Support and Gut Health. A small randomized double-blind placebo-controlled pilot trial in 80 adults with gastrointestinal discomfort and constipation found that 500 mg a day improved stool consistency for the whole group and eased bloating and feeling of fullness…

What is the recommended dosage of EpiCor?

The clinically studied dose is 500 mg/day. Always follow the product label and check with a healthcare provider for personal advice.

Is EpiCor safe, and does it have side effects?

Side effects and cautions reported for EpiCor include: Generally extremely well-tolerated. Mild GI distress (rare). It may also interact with some medications. EpiCor is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does EpiCor interact with any medications?

Possible interactions include: Generally minimal drug interactions. Yeast allergy: verify if allergic to baker's or brewer's yeast. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for EpiCor?

NutraSmarts rates the evidence for EpiCor as Limited (2 out of 5). It is backed by 2 study summaries and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Moyad MA, Robinson LE, Zawada ET Jr, Kittelsrud JM, Chen DG, Reeves SG, Weaver SE. Effects of a modified yeast supplement on cold/flu symptoms. Urol Nurs. 2008;28(1):50-5..PubMedUsed to support: Brand-specific (EpiCor, 500 mg/d, 12 weeks) RCT in 116 adults: fewer and shorter cold/flu symptoms vs placebo. Cohort had recent influenza vaccination. Small single-site trial; manufacturer-affiliated authors.
  2. Moyad MA, Robinson LE, Zawada ET, Kittelsrud J, Chen DG, Reeves SG, Weaver S. Immunogenic yeast-based fermentate for cold/flu-like symptoms in nonvaccinated individuals. J Altern Complement Med. 2010;16(2):213-8. doi: 10.1089/acm.2009.0310.PubMedUsed to support: Brand-specific (EpiCor, 500 mg/d, 12 weeks) RCT in 116 non-vaccinated adults: significantly reduced incidence of cold/flu-like symptoms vs placebo (no significant effect on severity). Companion to the 2008 study; small sample; manufacturer-affiliated.
  3. Evans M, Reeves S, Robinson LE. A dried yeast fermentate prevents and reduces inflammation in two separate experimental immune models. Evid Based Complement Alternat Med. 2012;2012:973041. doi: 10.1155/2012/973041.PubMedUsed to support: Brand-specific (EpiCor dried yeast fermentate) mechanistic study: reduced acute inflammation (rat carrageenan model) and established autoimmune arthritis (mouse collagen model). Preclinical (not human) and manufacturer-funded; supports anti-inflammatory mechanism rather than a clinical outcome.
  4. Pinheiro I, Robinson L, Verhelst A, Marzorati M, Winkens B, den Abbeele PV, Possemiers S. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial. BMC Complement Altern Med. 2017;17(1):441. doi:10.1186/s12906-017-1948-0.PubMedUsed to support: Single small manufacturer-linked pilot RCT (n=80): 500 mg/day EpiCor improved GI discomfort/constipation-related symptoms vs placebo. The main direct gut-health evidence; a small pilot.
  5. Singh RG, Garcia-Campayo V, Green JB, Paton N, Saunders JD, Al-Wahsh H, Crowley DC, Lewis ED, Evans M, Moulin M. Efficacy of a yeast postbiotic on cold/flu symptoms in healthy children: A randomized-controlled trial. Pediatr Res. 2024;96(7):1739-1748. doi: 10.1038/s41390-024-03331-z.PubMedUsed to support: Manufacturer-funded pediatric trial in 256 children: good tolerability and significantly lower overall cold and flu symptom severity than placebo, with less cold and flu medication use, but no significant reduction in symptom incidence.